|1.||Iacobelli, Massimo: 7 articles (04/2012 - 01/2006)|
|2.||Richardson, Paul G: 6 articles (01/2013 - 06/2007)|
|3.||Carreras, Enric: 3 articles (02/2015 - 08/2012)|
|4.||Corbacioglu, Selim: 3 articles (01/2013 - 04/2012)|
|5.||Revta, Carolyn: 3 articles (06/2012 - 06/2007)|
|6.||Palumbo, Antonio: 3 articles (03/2012 - 02/2009)|
|7.||Richardson, Paul: 3 articles (07/2010 - 01/2006)|
|8.||Niederwieser, Dietger: 2 articles (01/2013 - 08/2012)|
|9.||Soiffer, Robert: 2 articles (01/2013 - 08/2012)|
|10.||Hoyle, Margaret: 2 articles (01/2013 - 04/2012)|
|1.||Hepatic Veno-Occlusive Disease (Disease, Hepatic Veno-Occlusive)
08/01/2012 - "Safety and efficacy of defibrotide for the treatment of severe hepatic veno-occlusive disease."
07/01/2010 - "Therapeutic options for severe hepatic veno-occlusive disease (VOD) are limited and outcomes are dismal, but early phase I/II studies have suggested promising activity and acceptable toxicity using the novel polydisperse oligonucleotide defibrotide. "
12/01/2000 - "Defibrotide for the treatment of hepatic veno-occlusive disease: results of the European compassionate-use study."
12/01/2015 - "Escalation to High-Dose Defibrotide in Patients with Hepatic Veno-Occlusive Disease."
11/01/2014 - "Diagnosis of sinusoidal obstruction syndrome by positron emission tomography/computed tomography: report of two cases treated by defibrotide."
02/01/2002 - "1. The purpose of this study was to investigate the protective effects of defibrotide, a single-stranded polydeoxyribonucleotide, on ischaemia-reperfusion injury to the liver using a rat model. "
12/01/2003 - "The protective mechanisms of defibrotide on liver ischaemia-reperfusion injury."
02/01/2002 - "Effects of defibrotide, a novel oligodeoxyribonucleotide, on ischaemia and reperfusion injury of the rat liver."
01/01/1993 - "In fact, we showed that defibrotide treatment significantly protected rat heart, kidney and liver from ischaemia and postischaemic reperfusion injury. "
10/01/1990 - "Protection of kidney from postischemic reperfusion injury in rats treated with defibrotide."
|3.||Venous Thrombosis (Deep-Vein Thrombosis)
07/01/1988 - "In an open multicenter comparative study aimed at the evaluation of the efficacy of defibrotide in the prophylaxis of postsurgical deep vein thromboses (DVT) an ad interim evaluation has been made on 2626 patients thus far enrolled. "
01/01/1992 - "Prophylaxis of venous thrombosis after gynaecological surgery: a controlled pilot study of defibrotide."
05/31/1989 - "[A multicenter study of defibrotide in the prevention of deep venous thrombosis. "
05/01/1989 - "Thrombolytic activity of defibrotide: a morphometric evaluation in experimental venous thrombosis."
07/01/1988 - "[Defibrotide in the prevention of deep venous thrombosis in general surgery. "
05/15/1989 - "The efficacy of defibrotide in the treatment of acute thrombophlebitis of the legs has been investigated in 140 patients, randomized into two groups. "
12/15/1988 - "[Evaluation of the efficacy of profibrinolytic treatment with defibrotide in the therapy of thrombophlebitis]."
05/15/1989 - "[Use of defibrotide in the treatment of acute superficial thrombophlebitis of the legs]."
06/01/2004 - "The number of episodes of superficial thrombophlebitis and deep vein thrombosis was significantly lower under defibrotide (n=2) than under placebo (n=10). "
02/01/1993 - "Trials performed to date have provided initial evidence that defibrotide is effective in the treatment of peripheral obliterative arterial disease and acute thrombophlebitis, while preliminary data suggest possible use in preventing fibrin deposition in the circuitry of renal haemodialysis equipment. "
01/01/1987 - "The results show that Defibrotide is highly effective in reducing the size of the thrombus. "
10/01/1989 - "Defibrotide was effective against 3-, 7-, or 10-day-old thrombi; its ED50s were 32, 65, or 118 mg/kg-1 hour-1, respectively, suggesting that the age of the thrombus could play a role in the outcome of thrombolysis. "
01/01/1992 - "We think that the antithrombotic activity of Defibrotide is based on other factor(s) in addition to profibrinolytic activity, i.e., some scavenger activity and desensitization of cells involved in thrombus formation must also be taken into account."
01/01/1988 - "A number of different drugs modified thrombus formation in this model, for instance, ASA, defibrotide, unfractionated or low molecular heparins. "
01/01/1986 - "Because of these properties, defibrotide has antithrombotic effects which are demonstrated in various experimental models of venous and arterial thrombosis. "
|2.||calcium heparin (Calciparine)
|3.||DNA (Deoxyribonucleic Acid)
|10.||Plasminogen Activators (Plasminogen Activator)
|1.||Stem Cell Transplantation
|2.||Gynecologic Surgical Procedures (Gynecologic Surgery)
|3.||Bone Marrow Transplantation (Transplantation, Bone Marrow)